The World Health Assembly in 2016 called for the global eradication of viral hepatitis by 2030, setting global goals of a 90 percent reduction in new cases of hepatitis B and C, a 65 percent reduction in hepatitis B and hepatitis C deaths, and treatment of 80 percent of people living with these infections. Individual countries are now creating their own viral hepatitis elimination plans at various stages. Antiviral therapy for hepatitis B aims to lower a patient's risk of progressive liver disease by suppressing and eradicating HBV infection to a near-zero level, as well as arresting and ameliorating HBV-related liver damage. Treatment of acute and chronic hepatitis B with Phyllanthus urinaria, Adenosma Glutinosum, Eclipta Prostrata, Ascorbic Acid, Cyanocobalamin, and Tenofovir. The method entails combining medications generated from both natural and synthetic sources. This study has a greater impact on the immune system and is more successful at preventing HBV replication. This is a significant new insight into the disease's pathophysiology, with a clear path to clinical application, or which would lead to a significant and ideal advance in management or public health policy. The planned research chemical for the eradication of the hepatitis B virus has performed its assigned mission during the actual follow-up of this medication being applied to patients for more than 10 years.
Author(s) Details
Nguyen Thi Trieu
Saigon Biopharma Company limited, Ho Chi Minh City, Vietnam.
Tran Minh Duc
Saigon Biopharma Company limited, Ho Chi Minh City, Vietnam.
No comments:
Post a Comment